Company Profile


 28023 MADRID
Phone : +34 91 663 2500

   GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our broad expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, drug discovery, biopharmaceutical manufacturing technologies, performance improvement and performance solutions services help our customers to deliver better care to more people around the world at a lower cost. In addition, we partner with healthcare leaders, striving to leverage the global policy change necessary to implement a successful shift to sustainable healthcare systems.
    Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 42,100 people in 75 countries and markets its products in more than 180 countries. For more information, visit Facebook, Twitter, LinkedIn, YouTube

As a leading global healthcare and diagnostics company, we strive to make advances toward greater certainty for our customers by providing them with cutting-edge technology that makes a real difference. We move to narrow the gap between doubt and confidence and work to achieve both incremental and transformational progress to improve patients' lives.
We are passionate and resolute in our purpose; we call it The Science of Sure. This ethos is extended throughout our core offerings: Breast & Skeletal Health, Diagnostic, and GYNSurgical Solutions. We believe it is our responsibility to offer our customers ever-greater certainty – what we call progressive certainty – by pushing the boundaries of science.
We act with integrity. We innovate with determination. We are Hologic.

Natera is a leading genetic testing company that develops and commercializes non-invasive methods for analyzing DNA. The mission of the company is to transform the diagnosis and management of genetic disease.
In pursuit of that mission, Natera operates a CAP-accredited laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, CA, and it currently offers a host of proprietary genetic testing services primarily to OB/GYN physicians and fertility centers, as well as to genetic laboratories through its direct sales force, laboratory distribution partners, and licensees that can run tests in their own laboratories and have the data analyzed through Natera's cloud-based Constellation™ software system.

NIPD Genetics is an innovative European biotechnology company active in the field of designing, developing, and manufacturing non-invasive genetic tests.
 NIPD Genetics was founded in 2010 as a spin-off from the Cyprus Institute of Neurology and Genetics to commercialize pioneering research work in the field of non-invasive prenatal diagnosis.
 NIPD Genetics leverages its proprietary genetic and bioinformatic analysis methods to develops novel technologies for prediction and diagnosis of genetic disorders.
 NIPD Genetics launched the VERACITY non-invasive prenatal test for the detection of trisomies of chromosomes 21, 18, 13, and aneuploidies of X and Y in 2015.

Nutricia Research is the R&D organization behind Danone Nutricia Early Life Nutrition and Nutricia Advanced Medical Nutrition. We bring health through food to as many people as possible, particularly those who need special care.
Science is at the very heart of our nutrition and health commitment. Thus we focus our skills and resources on research and innovation to deliver evidence-based specialized nutrition to infants, young children, pregnant women, patients and the elderly. This helps individuals to build, establish and preserve their health capital during early life and later in life. 
The main center for Nutricia Research is located on the Utrecht Science Park, The Netherlands, with satellites in Asia, North America and Latin America. Our scientists, nutritionists and technologists operate within a strong worldwide network of global and local partners, all key specialists in their fields, including research institutes, universities, and academic hospitals.



Roche Diagnostics International Ltd.
Centralised and Point of Care Solutions
Forrenstrasse 2
6343 Rotkreuz, Switzerland

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Wisepress Medical Bookshop
15 Lyon Road
SW19 2RL
Phone: +44 20 8715 1812, Europe’s leading conference bookseller, attend around 200 conferences every year. We have an extensive range of books and journals relevant to the themes of this conference available at our booth. We also have a comprehensive range of STM titles available on our online bookshop. Follow us on Twitter @WisepressBooks.   



Mustionkatu 6
20750 Turku
Contact person: 
Ms. Tytti Massinen (
Tel: +971 50 5027894

PerkinElmer is a global company focused on improving the health and safety of people and their environment. Within the field of fetal and maternal healthcare, PerkinElmer offers complete screening solutions including instrumentation, reagents and risk calculation software for early detection of pregnancy related anomalies.
PerkinElmer was chosen as the principal screening partner for ASPRE. Throughout the study, the PerkinElmer DELFIA® Xpress PlGF 1-2-3TM assay was used as an aid in screening for pre-eclampsia in conjunction with maternal history, mean arterial blood pressure (MAP) measurement, and uAD (Uterine Artery Doppler). ASPRE is expected to report in 2017. 
PerkinElmer has recently acquired Vanadis Diagnostics, which is developing a novel non-sequencing, non-PCR based solution for cfDNA analysis. In the future this acquisition will able PerkinElmer to offer a simplified, cost-effective, high-throughput screening test to help facilitate wider access to non-invasive prenatal testing for pregnant women.
Maternal fetal products availability and claims may differ from country to country based on regulations and product approvals. Please check availability with your local distributor.